NEW YORK, June 11 – Canada’s Virtek Vision International said Monday that its Virtek ChipWriter and Virtek ChipReader had been selected for a six-month trial to apply its microarray technology for a neonatal screening application.

Under the terms of the alliance, Virtek has agreed to supply its spotter and reader to Neo Gen Screening and TeleChem International/ArrayIt.com for the testing of metabolic disorders in newborns. TeleChem of Sunnyvale, Calif., has developed the assays while Neo Gen Screening of Pittsburgh, Pa., develops tests for screening disorders.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.